Syndecan-1 messenger RNA (SDC1 mRNA)

Syndecan-1 (SDC1) mRNA encodes a transmembrane heparan sulfate proteoglycan that is essential for mediating cell-matrix interactions and growth factor signaling (UniProt P18827). This protein acts as a co-receptor for various growth factors and chemokines, facilitating signaling pathways involved in cell proliferation, survival, and angiogenesis (NCBI Gene ID 6382). In multiple myeloma, SDC1 is highly overexpressed and serves as a hallmark diagnostic marker and a key driver of tumor progression (PMID: 15150099). Targeting the SDC1 mRNA specifically allows for the downregulation of both the membrane-bound and shed forms of the protein, which can be advantageous over protein-targeting antibodies that may be sequestered by soluble CD138. Experimental approaches using siRNA or antisense oligonucleotides have shown efficacy in reducing tumor growth and inducing apoptosis in preclinical cancer models (PMID: 25605525). Beyond oncology, SDC1 mRNA expression is modulated during inflammatory processes and wound healing, indicating a broader biological role in tissue homeostasis. Despite its potential, the clinical application of SDC1 mRNA-targeted therapies is currently limited by the need for effective delivery systems to reach plasma cells or solid tumor sites. Safety concerns include potential off-target effects and the impact on normal epithelial tissues where Syndecan-1 maintains structural integrity.

Other names

CD138 mRNASYND1 mRNASyndecan-1 mRNASDC1 transcript

RNA interference (RNAi) or antisense-mediated degradation of SDC1 mRNA, leading to reduced expression of the Syndecan-1 protein and subsequent inhibition of oncogenic signaling and cell adhesion.